Elevation Oncology Q1 net loss $10.7M; cash $104.1M; EO-3021 trial ongoing

Elevation Oncology, Inc.

Net loss of $10.7M improved from $17.1M in Q1 2023; R&D expenses $6.0M, G&A $3.9M.
Cash and marketable securities $104.1M at March 31, 2024; raised $44.2M YTD via ATM, extending runway into 2026.
Enrollment ongoing in Phase 1 trial of EO-3021 (Claudin 18.2 ADC); initial safety/efficacy data expected by mid-3Q 2024.
Presented preclinical proof-of-concept for HER3-ADC program at AACR; development candidate nomination planned for 2H 2024.
Plans to share details of EO-3021 combination study in 1H 2024; additional data expected in 1H 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Elevation Oncology, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Elevation Oncology, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

222 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-006455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.